Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Ahead
scheduled · today and tomorrow · calendar refreshed 2026-10-12
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU 2.7mg in Wet AMD
EyePoint released topline Phase 3 LUGANO data for DURAVYU (vorolanib intravitreal insert) in wet AMD. Per the release, "The primary endpoint of change from baseline in best corrected visual acuity (BCVA) versus 2 mg aflibercept on-label control was not achieved in the full dataset." The release adds that DURAVYU "was non-inferior to on-label aflibercept (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (>= 15 letters) unrelated to wet AMD," and reports a 42% reduction in treatment burden versus aflibercept (p-value <0.0001). The on-label 2 mg aflibercept comparator is Regeneron's Eylea; a missed head-to-head primary endpoint by the leading long-duration challenger is relevant to Regeneron's anti-VEGF franchise.
Kratos and GE Aerospace's GEK800 wins USAF EMD contract as second-source JASSM engine, gets F143-ZZ-100 designation
Kratos Defense & Security Solutions and GE Aerospace announced that the GEK800 engine, which received the U.S. Military Engine Type Designation F143-ZZ-100, has been awarded a contract with the United States Air Force for the Engineering, Manufacturing and Development (EMD) of the turbofan as a second-source propulsion system for the Joint Air-to-Surface Standoff Missile (JASSM). The release states Kratos and GE Aerospace began working together in 2023 to complete a Technology Maturation and Risk Reduction (TMRR) phase including testing of the engine.
RTX's Raytheon awarded seven-year contract for Tomahawk cruise missiles
Raytheon, an RTX business, will accelerate production of Tomahawk cruise missiles for the U.S. Navy under a $22.9 billion seven-year contract awarded as part of the Department of War's Arsenal of Freedom, supporting an annual production ramp to more than 1,000 missiles.
NASA on-ramps Firefly Aerospace and L3Harris to $100 million Spacecraft Processing Operations Contract
NASA selected All Points Logistics LLC, Blue Origin LLC, Firefly Aerospace and L3Harris Technologies Inc. under the on-ramp provision of its Spacecraft Processing Operations Contract. The contract has a ceiling value of $100 million and a period of performance through February 1, 2033, and covers the facilities and services required to perform prelaunch processing of spacecraft and associated rocket hardware for delivery to the launch pad. The on-ramp lets these vendors furnish commercial payload processing for agency missions launching from locations where such capability was not available at the time of the initial award.
HII's Newport News Shipbuilding completes acceptance sea trials of carrier John F. Kennedy (CVN 79)
HII's Newport News Shipbuilding division completed acceptance sea trials of John F. Kennedy (CVN 79), the second Gerald R. Ford-class nuclear-powered aircraft carrier. HII said that with the successful completion of acceptance trials, the next step for the ship is preliminary acceptance, which will enable the Navy to begin underway test and evaluation of Kennedy's unique systems. Builder's sea trials had been completed earlier in 2026.
